For a life free from pain, and for control over our minds.

Careers

When our health collapses, we treat it as an emergency.

When we live for decades with chronic pain or mental health disorders, we treat it as just part of life.

Samphire builds advanced brain based technologies to change this status quo.

Our story2022

Cumulative stimulation0 mins

Founded

The goal was to develop treatments that improve the lives of those living with chronic pain and mood conditions.

Targets identified

PMDD, dysmenorrhea, perimenopause, chronic migraines and endometriosis all identified as targets.

First devices

The first version of the Samphire Headband (Nettle™) was built.

Usability tests

Hundreds of women were involved in testing early versions. The purpose was to develop a safe, effective, easy to use, aesthetic, comfortable medical device that could transform lives.

Quality system

Samphire was certified under ISO13485 as a manufacturer of quality medical devices.

First clinical trials

A double-blind, randomised controlled trial demonstrated that the Samphire Headband outperformed placebo and existing options for premenstrual mood and period pain (dysmenorrhea).

Regulator approval

The Samphire Headband (under the name Nettle™) was granted Class IIa medical device clearance in the United Kingdom and European Union.

Market access

The Samphire Headband (under the name Nettle™) became available to users across the United Kingdom and European Union.

Sold out

A limited number of Samphire Headbands were released directly to users. Over 87% of people who used the Headband said that it “transformed [their] lives.”

PMDD clinical trials

Samphire completed clinical trials demonstrating efficacy for premenstrual dysphoric disorder (PMDD). 82.4% of people achieved an over-30% reduction in their anxiety symptoms, significantly outperforming placebo in a double-blind randomised control trial.

Endo clinical trials

Samphire completed clinical trials demonstrating efficacy for endometriosis (Endo). 71.0% of people experienced reduced pain, significantly outperforming placebo in a double-blind randomised control trial.

USA access

Completing clinical investigations to be available as a prescribed option for pain management in endometriosis, and mood management in PMDD and perimenopause.